![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
July 10, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more
June 11, 2025
The changes broaden eligibility and clarify treatment planning details in this phase 2 trial testing daratumumab-hyaluronidase to eliminate minimal residual disease after initial chemotherapy
March 21, 2025
Summaries of recently published ECOG-ACRIN and PrECOG research results
March 21, 2025
Summaries and links to timely information about research results presented at medical meetings, recognition of research leaders, and more
February 19, 2025
Seven ground-breaking findings from cancer clinical trials in 2024 by ECOG-ACRIN and PrECOG
December 23, 2024
Summaries of presentations at the 2024 San Antonio Breast Cancer Symposium as well as the 66th American Society of Hematology Annual Meeting and Exposition in San Diego
November 25, 2024
October 17, 2024
Summaries of recently published ECOG-ACRIN research results
September 17, 2024
Summaries of recently published ECOG-ACRIN research results
September 17, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 14, 2024
Thoughts on the evolving clinical cancer research environment—and practice-changing results in acute lymphoblastic leukemia
August 14, 2024
A Scientific Member of ECOG-ACRIN since 2012